Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AB801 Monotherapy and Combination Therapy in Advanced Malignancies
NCT06120075Phase 1Completed
- Sponsor
- Arcus Biosciences
- Start
- Jan 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of AB801 in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), breast cancer and 4 more (8 cohorts), sponsored by Arcus Biosciences. Primary endpoints: Number of Participants With Adverse Events up to 2 years and Number of Participants With Dose-Limiting Toxicities up to 2 years. Started Jan 2024; status: completed.
02
Drugs
AB801
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)breast cancerovarian cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06120075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06120075.